Brief: Enzychem Files For FDA Breakthrough Therapy Designation For EC-18 For The Treatment Of Chemoradiation-Induced Oral Mucositis
08/11/2021 18:06
Nov 8 (Reuters) - Enzychem Lifesciences Corp 183490.KQ :
* ENZYCHEM FILES FOR FDA BREAKTHROUGH THERAPY DESIGNATION
FOR
EC-18 FOR THE TREATMENT OF CHEMORADIATION-INDUCED ORAL MUCOSITIS
* ENZYCHEM LIFESCIENCES CORP - BTD FILING IS BASED ON DATA
FROM
COMPANY'S PHASE 2 TRIAL.
Source text for Eikon: ID:nBw3rNmfha
Further company coverage: 183490.KQ
((Reuters.briefs@thomsonreuters.com;))
Recent news on Enzychem Lifesciences
See all newsBrief: Enzychem Lifesciences To Divest 8 Billion Won Worth Of Own Shares
Brief: Enzychem Lifesciences Announces Completion Of Clinical Study Report (Csr) For Phase 2 Study Of Ec-18 In Chemoradiation-Induced Oral Mucositis
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot (updated)
Brief: Cadila Healthcare Inks Deal With South Korea's Enzychem For Plasmid DNA Vaccine
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot